(Q33401450)

26 July 2017

title

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors (English)

1 reference

26 July 2017

1 reference

5

Gerard C Blobe

1 reference

26 July 2017

Gordana Vlahovic

1

1 reference

26 July 2017

Kellen L Meadows

2

1 reference

26 July 2017

Hope E Uronis

3

1 reference

26 July 2017

Michael A Morse

4

1 reference

26 July 2017

Richard F Riedel

6

1 reference

26 July 2017

S Yousuf Zafar

7

1 reference

26 July 2017

Angeles Alvarez-Secord

8

1 reference

26 July 2017

Jon Gockerman

9

1 reference

26 July 2017

Alexander N Starodub

10

1 reference

26 July 2017

Neal E Ready

11

1 reference

26 July 2017

Elizabeth L Anderson

12

1 reference

26 July 2017

Johanna C Bendell

13

1 reference

26 July 2017

Herbert I Hurwitz

14

1 reference

26 July 2017

publication date

26 May 2012

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

70

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

95-102

1 reference

Treatment of non-small-cell lung cancer with erlotinib or gefitinib

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Targeting the mTOR signaling network for cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Beyond chemotherapy: targeted therapies in ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

EGFR antagonists in cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Targeting the mTOR signaling network in cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Defining the role of mTOR in cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

The epidermal growth factor receptor pathway: a model for targeted therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Epidermal growth factor receptor (EGFR) signaling in cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Epidermal growth factor receptor in tumor angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

The biology of VEGF and its receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1889-8

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1889-8

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1889-8

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1889-8

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1889-8

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1889-8

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1889-8

Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086794

Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22638798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Accelerated titration designs for phase I clinical trials in oncology

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22638798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22638798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-012-1889-8

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference